|
|
||||||||
1 Cancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington; 2 Division of General Internal Medicine and 3 Department of Pharmacy, University of Washington, Seattle, Washington; and 4 Department of Health Services, University of California, Los Angeles, California
Correspondence and requests for reprints should be addressed to Scott D. Ramsey, M.D., Ph.D., Fred Hutchinson Cancer Research Center, Public Health Sciences Division, 1100 Fairview Avenue North (M3-B232), Seattle, WA 98109. E-mail: sramsey{at}fhcrc.org.
ABSTRACT
Lung volume reduction surgery (LVRS) is a costly procedure that can improve quality and quantity of life. Given the prevalence of emphysema, the costs involved with its management, and resource constraints on all health care delivery systems, evaluating the cost-effectiveness of LVRS is important. In this article, we describe the purposes and principles of cost-effectiveness analysis and how those principles were applied in evaluating LVRS. We present the results of the cost-effectiveness analysis that was conducted alongside the National Emphysema Treatment Trial and other economic studies of LVRS and discuss how these should be interpreted in the context of current reimbursement guidelines.
Key Words: emphysema lung volume reduction surgery clinical trial cost-effectiveness quality-adjusted life-years
Related articles in Proceedings of the American Thoracic Society:
This article has been cited by other articles:
![]() |
R. M. Kaplan and A. L. Ries Health-related Quality of Life in Emphysema Proceedings of the ATS, May 1, 2008; 5(4): 561 - 566. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |